The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
The ninth acquisition since 2018
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Collaboration supports multiple discovery efforts, including vaccines
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Investment in response to increased demand for North American-based chemistry services
Completion of the demerger of Haleon and share consolidation of GSK
Subscribe To Our Newsletter & Stay Updated
